Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value

Author:
  • J Vandesompele
  • Anders Edsjö
  • K De Preter
  • Håkan Axelson
  • F Speleman
  • Sven Påhlman
Publishing year: 2003
Language: English
Pages: 456-460
Publication/Series: Oncogene
Volume: 22
Issue: 3
Document type: Journal article
Publisher: Nature Publishing Group

Abstract english

The MYCN proto-oncogene is frequently amplified in a subgroup of highly aggressive neuroblastomas. The molecular mechanism(s) by which the overexpressed MYCN contributes to an aggressive tumor cell behavior is not well understood. Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma. In addition, ID2 expression was proposed as a negative prognostic parameter. As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated. We found no correlation between MYCN and ID2 expression in neuroblastoma cell lines or tumor specimens. However, we did find a significant positive correlation between MYC and ID2 expressions in both MYCN-amplified and single-copy tumor specimens, and in MYCN single-copy cell lines. As previously reported, we also found an inverse correlation between MYC and MYCN expressions. Importantly, we could not confirm the reported prognostic power of ID2-expression in neuroblastoma. These data, obtained in two independent laboratories, challenge the previously proposed ID2-MYCN relation.

Keywords

  • Cancer and Oncology
  • prognosis
  • neuroblastoma
  • MYCN
  • ID2
  • MYC

Other

Published
  • ISSN: 1476-5594
Håkan Axelson
E-mail: hakan.axelson [at] med.lu.se

Professor

Division of Translational Cancer Research

+46 46 222 64 34

MV 404 A31A2

90